To support the work of NHS England the role holders will: be the lead clinical advisors to NHS England regarding cancer medicines, using their outstanding knowledge of the clinical and economic evidence base. work collaboratively across NHS England and the wider health system to improve the quality and value of healthcare services and ensure the implementation of new cancer medicines is clinically focused and credible. be accountable for NHS Englands clinical input into NICE technology appraisals for cancer drugs, representing NHS England at committee meetings. support commercial negotiation and policy teams with horizon scanning, and in the design and delivery of intervention and resources to support system, professional and care pathway changes at a national and local level. be responsible for the provision of high-quality clinical leadership and advice to ensure the Cancer Drugs Fund continues to operate effectively, meets its aims and has high quality clinical input into its activity. build effective working relationships with key stakeholders, including the pharmaceutical industry, NHS organisations, regulators and professional bodies. lead the development of NHS England clinical treatment criteria for all new NICE approved cancer medicines, translating the evidence base from the drug licensing and NICE recommendation into criteria that places the drug within the existing clinical pathway. provide clinical input into considerations of commercial activity in line with the NHS England Commercial Framework for medicines. provide clinical input into responses to MP letters and parliamentary questions. represent the CDF, MVA and NHS England at National engagements. NHS England requires its advisorsto maintain a high standard of confidentiality and all individuals are subject to the requirements of the Data Protection Act 1998. NHS Englands Confidentiality Policy can be viewed here: